TITLE

Lessons Learned from HIV Treatment Interruption: Safety, Correlates of Immune Control, and Drug Sparing

AUTHOR(S)
Azzoni, Livio; Papasavvas, Emmanouil; Montaner, Luis J.
PUB. DATE
July 2003
SOURCE
Current HIV Research;Jul2003, Vol. 1 Issue 3, p329
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Therapeutic approaches seeking to limit the exposure to antiretroviral drugs while retaining the benefits of continuous therapy have become an active area of investigation in HIV therapy research. Although early attempts to use interruptions of therapy as auto-vaccination strategies have shown little success, much has been discovered in regards to immunological correlates of viral control in acute and chronic infection, viral evolution, and the safety of single or multiple therapy interruptions in different patient sub-groups (acutely infected, chronically infected, and multi-drug resistant). Here we review safety data and candidate factors that may contribute to the striking differences observed between patients that undergo similar treatment interruption strategies but achieve different outcomes in controlling HIV replication. Differences between acute and chronic infection in the viral component (e.g. diversity of the viral pool) and the host immune system (e.g. low avidity CTL memory response), which may not be reversed by ART, may determine the potential for suppressive immune response upon therapy interruption. Consistent with goals of limiting toxicity and cost of antiretroviral drug regimens, safety outcomes to date indicate that intermittent therapy strategies may safely continue to be investigated in early and chronically infected patients. Based on ongoing research, we identify the topics to be targeted in future studies.
ACCESSION #
11946477

 

Related Articles

  • Uganda to double use of antiretrovirals in people with HIV. Wasswa, Henry // BMJ: British Medical Journal (International Edition);9/13/2008, Vol. 337 Issue 7670, p596 

    The article reports on Uganda's plans to introduce a program to increase the number of people infected with the HIV virus who are treated with antiretroviral drugs, and to set a new CD4 count of 350 cells at which patients will be given the antiretroviral treatments. A discussion of the...

  • Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients Receiving Antiretroviral Therapy: Pathogenesis, Clinical Manifestations and Management. Dhasmana, Devesh J.; Dheda, Keertan; Ravn, Pernille; Wilkinson, Robert J.; Meintjes, Graeme // Drugs;2008, Vol. 68 Issue 2, p191 

    The use of antiretroviral therapy (ART) to treat HIV infection, by restoring CD4+ cell count and immune function, is associated with significant reductions in morbidity and mortality. Soon after ART initiation, there is a rapid phase of restoration of pathogen-specific immunity. In certain...

  • Bigger T-cell response not necessarily better. Minton, Kirsty // Nature Reviews Immunology;Feb2007, Vol. 7 Issue 2, p88 

    The article discusses a study about T cell response to treat HIV. Many medical researchers focus on using T cell response specifically for HIV in order to prevent progression. The study suggests that it is important to define the specific T cell response for people who have progressed to having...

  • Baseline characteristics, response to and outcome of antiretroviral therapy among patients with HIV-1, HIV-2 and dual infection in Burkina Faso Harries, Katie; Zachariah, Rony; Manzi, Marcel; Firmenich, Peter; Mathela, Richard; Drabo, Joseph; Onadja, G.; Arnould, Line; Harries, Anthony // Transactions of the Royal Society of Tropical Medicine & Hygiene;Feb2010, Vol. 104 Issue 2, p154 

    Summary: In an urban district hospital in Burkina Faso we investigated the relative proportions of HIV-1, HIV-2 and HIV-1/2 among those tested, the baseline sociodemographic and clinical characteristics, and the response to and outcome of antiretroviral therapy (ART). A total of 7368 individuals...

  • Neurocognitive Impairment in HIV-Infected Naïve Patients with Advanced Disease: The Role of Virus and Intrathecal Immune Activation. Airoldi, Monica; Bandera, Alessandra; Trabattoni, Daria; Tagliabue, Benedetta; Arosio, Beatrice; Soria, Alessandro; Rainone, Veronica; Lapadula, Giuseppe; Annoni, Giorgio; Clerici, Mario; Gori, Andrea // Clinical & Developmental Immunology;2012, p1 

    Objective. To investigate intrathecal immune activation parameters and HIV-RNA in HIV-associated neurocognitive disorders (HAND) of advanced naïve HIV-infected patients and to evaluate their dynamics before and after initiation of antiretroviral therapy (ART). Methods. Cross-sectional and...

  • Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study. Murray, Daniel D.; Suzuki, Kazuo; Law, Matthew; Trebicka, Jonel; Neuhaus, Jacquie; Wentworth, Deborah; Johnson, Margaret; Vjecha, Michael J.; Kelleher, Anthony D.; Emery, Sean; null, null // PLoS ONE;10/14/2015, Vol. 10 Issue 10, p1 

    Introduction: The use of anti-retroviral therapy (ART) has dramatically reduced HIV-1 associated morbidity and mortality. However, HIV-1 infected individuals have increased rates of morbidity and mortality compared to the non-HIV-1 infected population and this appears to be related to end-organ...

  • Therapeutic Immunization with Dendritic Cells Loaded with Heat-Inactivated Autologous HIV-1 in Patients with Chronic HIV-1 Infection. García, Felipe; Lejeune, Merylene; Climent, Nuria; Gil, Cristina; Alcami, José; Morente, Vanessa; Alós, Llucia; Ruiz, Alba; Setoain, Javier; Fumero, Emilio; Castro, Pedro; López, Anna; Cruceta, Anna; Piera, Carlos; Florence, Eric; Pereira, Arturo; Libois, Agnes; Gonzalez, Nuria; Guilá, Meritxell; Caballero, Miguel // Journal of Infectious Diseases;5/15/2005, Vol. 191 Issue 10, p1680 

    Therapeutic immunization with autologous monocyte-derived dendritic cells (DCs) loaded with heat-inactivated autologous human immunodeficiency virus type 1 (HIV-1) in 12 patients with chronic HIV-1 infection who were receiving highly active antiretroviral therapy (HAART) was feasible, safe, and...

  • The Immunological Response after the Initiation of the Second Line Anti-Retroviral Therapy (ART) in HIV Patients. PILLAI, KEERTHI; RAMAPURAM, JOHN T.; ACHAPPA, BASAVAPRABHU; MADI, DEEPAK; CHOWTA, MUKTA N.; SATISH RAO, B.; MAHALINGAM, SOUNDARYA; UNNIKRISHNAN, B. // Journal of Clinical & Diagnostic Research;Sep2012, Vol. 6 Issue 7, p1171 

    Introduction: The treatment with the second line ART is initiated when the first line therapy fails. There is less experience with the immunologic response for the second-line ART for adults. Hence, this study was done to find out the immunological response after the initiation of the second...

  • Relationship between Regulatory T Cells and Immune Activation in Human Immunodeficiency Virus-Infected Patients Interrupting Antiretroviral Therapy. Weiss, Laurence; Piketty, Christophe; Assoumou, Lambert; Didier, Céline; Caccavelli, Laure; Donkova-Petrini, Vladimira; Levy, Yves; Girard, Pierre-Marie; Burgard, Marianne; Viard, Jean-Paul; Rouzioux, Christine; Costagliola, Dominique // PLoS Clinical Trials;Jul2010, Vol. 7 Issue 7, Special section p1 

    Persistent immune activation plays a central role in driving Human Immunodeficiency Virus (HIV) disease progression. Whether CD4+CD25+ regulatory T cells (Tregs) are harmful by suppressing HIV-specific immune responses and/or beneficial through a decrease in immune activation remains debatable....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics